Results 121 to 130 of about 112,964 (206)

Inflammasome activation contributes to cisplatin resistance in ovarian cancer. [PDF]

J Ovarian Res
de Souza JC, Pimenta TM, Martins BDS, Padilha JMS, Butzene SMS, Marçal MG, Rangel LBA.   +6 more
europepmc   +1 more source

NAT10 promotes cisplatin resistance and immune escape by increasing the expression of DUSP1 and PD-L1 in gastric cancer. [PDF]

Cell Death Discov
Qian L, Gao W, Wang X, Cui S, Han X, Xu X, Jia J, Liu Z.   +7 more
europepmc   +1 more source

DTX3L promotes ovarian cancer progression and cisplatin resistance by activating JAK1/STAT1/OAS3 pathway. [PDF]

Sci Rep
Lu F, Zhou Y, Wei Y, Mo S, Tan J, Kuang Y.   +5 more
europepmc   +1 more source

Correction: CLC3 regulates V-ATPase to enhance lysosomal degradation and cisplatin resistance in cervical cancer cells. [PDF]

Cell Death Discov
Chen C, Zhang F, Shen J, Zheng Q, Zhang Z, Lu S, Liu L, Zhu T, Du Y, Guan Y.   +9 more
europepmc   +1 more source

Cisplatin resistance reversal by disulfiram and caffeine

Journal of Pharmacology and Pharmacotherapeutics, 2016
Kadia, Ashish R., Shah, Gaurang B.
openaire   +3 more sources

Targeting epigenetic networks to overcome cisplatin resistance in ovarian cancer: from mechanisms to clinical translation. [PDF]

J Ovarian Res
Tang M, Wang Y, Xie Y, Li J, Ding D, Li C, Chen Q, Han F.   +7 more
europepmc   +1 more source

JPH3 Facilitates Cisplatin Resistance in Anaplastic Thyroid Cancer via Activation of the JAK-STAT Signaling Pathway. [PDF]

Cancer Med
Wang X, Luan S, Sun L, Lian L, Qi M.
europepmc   +1 more source

ESM1 drives cisplatin resistance and ferroptosis resistance via ERBB2/FAK/SRC/HSPB1/NF-κB signaling in ovarian cancer. [PDF]

iScience
Zhang J, Tan Y, Yang H, Tang X, Liu D, Zhou W, Zeng T, Liu X, Li M, Chen X, Zou J, Li Y.   +11 more
europepmc   +1 more source

HMGB1 Assists in Overcoming Cisplatin Resistance in Chemoresistant Human Ovarian Cancer Cells. [PDF]

Mol Carcinog
Huynh V, Wang G, Mukherjee A, Vasquez KM.   +3 more
europepmc   +1 more source

Targeting the METTL3/PCNA axis with STM2457 overcomes cisplatin resistance in osteosarcoma. [PDF]

Transl Cancer Res
Yu H, Li S, Liu J.
europepmc   +1 more source